Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

PhytoCeutica of the US to Advance Clinical Trials of TCM for Cancer

publication date: Apr 3, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
PhytoCeutica, a Connecticut pharma startup sponsored by Yale University, plans to move its lead drug, PHY906, forward in clinical trials as an adjuvant to chemotherapy. PHY906 is an ancient TCM known as Huang Qin Tang, used for the past 18 centuries as a treatment for diarrhea, nausea and vomiting. Yung-Chi Cheng, PhD, a distinguished pharmacologist at Yale University, discovered the TCM may be a valuable addition to chemotherapy. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors